Sanofi is advancing its innovation strategy through a series of strategic investments aimed at enhancing its pipeline in immune and oncology areas. The French global pharma leader has made a strategic equity investment in InduPro Therapeutics, supporting a collaboration to develop a novel bispecific PD-1 agonist for autoimmune and inflammatory disorders. The deal gives Sanofi funding support and rights to negotiate further on the program as it moves toward clinical development. 

In another move, Sanofi invested around €300 million in Orano Med, gaining a significant minority stake in the radioligand therapy developer focused on lead-212 based treatments for hard-to-treat rare cancers and gastroenteropancreatic neuroendocrine tumors. This investment strengthens Sanofi’s presence in innovative targeted therapies beyond traditional biologics. 

These investments reflect Sanofi’s broader commitment to early-stage biotech and emerging treatment modalities. The company, through its venture arm Sanofi Ventures, recently received an additional capital commitment to accelerate investment in biotech and digital health innovation, pointing to a sustained long-term strategy of backing breakthrough science.